Akero Therapeutics, Inc.
Akero Therapeutics, Inc. (AKRO) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · AKRO · as of Jun 8, 2026
Activity summary
Buy transactions
4
P-Purchase only
Sell transactions
118
12 Months
Buy/Sell ratio
0.03
Buy/Sell (by trades)
Overall sentiment
Akero Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
AKRO insider buying and selling by quarter
AKRO insider selling · AKRO insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · AKRO ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
AKRO executive sell shares · AKRO board member insider trading · AKRO insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Dec 9, 2025 | Heyman Tomas J. Director | Other | 9,398 | — | Form 4 |
| Dec 9, 2025 | Xu Yuan Director | Other | 9,398 | — | Form 4 |
| Dec 9, 2025 | Cheng Andrew President and CEO · Director | Other | 159,762 | — | Form 4 |
| Dec 9, 2025 | Harrison Seth Loring Director | Other | 9,398 | — | Form 4 |
| Dec 9, 2025 | Graham G. Walmsley Director | Other | 9,398 | — | Form 4 |
| Dec 9, 2025 | Judy Chou Director | Other | 9,398 | — | Form 4 |
| Dec 9, 2025 | Rolph Timothy Chief Scientific Officer | Other | 43,810 | — | Form 4 |
| Dec 9, 2025 | Iwicki Mark T Director | Other | 9,398 | — | Form 4 |
| Dec 9, 2025 | Gangloff Scott A. CTO | Other | 21,263 | — | Form 4 |
| Dec 9, 2025 | White William Richard CFO | Other | 47,573 | — | Form 4 |
| Dec 9, 2025 | Yale Catriona Chief Development Officer | Other | 47,573 | — | Form 4 |
| Dec 9, 2025 | Lamy Patrick See Remarks | Other | 26,832 | — | Form 4 |
| Dec 9, 2025 | Henderson Jane Director | Other | 9,398 | — | Form 4 |
| Dec 9, 2025 | Young Jonathan COO | Other | 47,573 | — | Form 4 |
| Nov 25, 2025 | Rolph Timothy Chief Scientific Officer | Option | 4,739 | $100K | Form 4 |
| Nov 25, 2025 | Rolph Timothy Chief Scientific Officer | Option | 94,268 | $58K | Form 4 |
| Nov 25, 2025 | Rolph Timothy Chief Scientific Officer | Option | 2,796 | $2K | Form 4 |
| Nov 25, 2025 | Rolph Timothy Chief Scientific Officer | Option | 4,284 | $90K | Form 4 |
| Nov 25, 2025 | Rolph Timothy Chief Scientific Officer | Option | 43,064 | $274K | Form 4 |
| Nov 25, 2025 | Rolph Timothy Chief Scientific Officer | Option | 3,527 | $100K | Form 4 |
| Nov 24, 2025 | Young Jonathan COO | Option | 4,739 | $100K | Form 4 |
| Nov 24, 2025 | Young Jonathan COO | Option | 3,527 | $100K | Form 4 |
| Nov 24, 2025 | Young Jonathan COO | Option | 4,284 | $90K | Form 4 |
| Nov 26, 2025 | Young Jonathan COO | Gift | 9,259 | — | Form 4 |
Cheng Andrew
President and CEO · Director
Date
Dec 9
Shares
159,762
Price
—
Value
—
Rolph Timothy
Chief Scientific Officer
Date
Nov 25
Shares
4,739
Price
$21.10
Value
$100K
Rolph Timothy
Chief Scientific Officer
Date
Nov 25
Shares
94,268
Price
$0.61
Value
$58K
Rolph Timothy
Chief Scientific Officer
Date
Nov 25
Shares
2,796
Price
$0.61
Value
$2K
Rolph Timothy
Chief Scientific Officer
Date
Nov 25
Shares
4,284
Price
$21.09
Value
$90K
Rolph Timothy
Chief Scientific Officer
Date
Nov 25
Shares
43,064
Price
$6.36
Value
$274K
Rolph Timothy
Chief Scientific Officer
Date
Nov 25
Shares
3,527
Price
$28.35
Value
$100K
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About AKRO insider trading
AKRO insider trades
Akero Therapeutics, Inc. (AKRO) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Rolph Timothy (Chief Scientific Officer), Young Jonathan (COO), Heyman Tomas J. (Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. AKRO insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Akero Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
AKRO insider trading · 5 questionsThe insiders of Akero Therapeutics, Inc. (AKRO) include executives and directors such as Rolph Timothy (Chief Scientific Officer), Young Jonathan (COO), Heyman Tomas J. (Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026